autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy

Class

autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy

Pathway

IV-administered autologous stem cells with immunomodulatory/wound-healing paracrine effect (upregulates CXCL8, CXCR1, CXCR2)

Autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy uses stem cells harvested from a patient's own fat tissue, expanded in the laboratory, and reinfused intravenously. Mesenchymal stem cells are multipotent cells that can influence surrounding tissue not primarily by replacing damaged cells but through a paracrine effect: they secrete a mixture of signaling proteins that modulate inflammation and support tissue repair. In this mechanism, the cells upregulate the chemokine CXCL8 (interleukin-8) and its receptors CXCR1 and CXCR2, a signaling axis involved in recruiting and coordinating immune cells at sites of injury or inflammation. Because the cells are autologous, they are derived from and returned to the same individual, which reduces the risk of immune rejection compared with donor-derived cell products. This approach is studied broadly across conditions characterized by chronic inflammation, impaired wound healing, tissue degeneration, or ischemic injury, since the underlying biological rationale is to modulate an overactive or dysregulated immune response while promoting regeneration of damaged tissue. The appeal of this mechanism lies in its multifactorial action: rather than blocking a single receptor or enzyme, it delivers a living cell population capable of sensing tissue conditions and adjusting its secreted signals accordingly.